Removal of Ticagrelor by Hemoadsorption with the HA380 Cartridge.

IF 1.8 3区医学 Q3 HEMATOLOGY Blood Purification Pub Date : 2025-01-01 Epub Date: 2025-02-18 DOI:10.1159/000544770

Taku Furukawa, Yugeesh R Lankadeva, Ian C Baldwin, Pei Chen Connie Ow, Sally Hood, Youssef Daali, Antoine Schneider, Laurent A Decosterd, Clive N May, Rinaldo Bellomo

{"title":"Removal of Ticagrelor by Hemoadsorption with the HA380 Cartridge.","authors":"Taku Furukawa, Yugeesh R Lankadeva, Ian C Baldwin, Pei Chen Connie Ow, Sally Hood, Youssef Daali, Antoine Schneider, Laurent A Decosterd, Clive N May, Rinaldo Bellomo","doi":"10.1159/000544770","DOIUrl":null,"url":null,"abstract":"Introduction: Hemoadsorption has emerged as a potential intervention for the removal of ticagrelor. We aimed to evaluate the efficacy of the HA380 hemoadsorption cartridge for this purpose.Methods: Six healthy adult sheep received 270 mg of ticagrelor via an orogastric tube, followed by hemoadsorption using a HA380 cartridge for a duration of 4 h. The sorbent-based removal ratio, clearance, and mass removal rate were assessed at multiple time points.Results: The HA380 cartridge achieved an initial sorbent-based removal ratio of 48.9% (SD 11.8) at 10 min, which declined rapidly to 2.66% (SD 18.5) at 120 min and 0.48% (SD 17.0) at 240 min. Clearance followed a similar trend, starting at 46.1 mL/min (SD 11.4) and decreasing to 0.08 mL/min (SD 16.8) at 240 min. The mass removal rate also dropped significantly over time, from 3.74 ng/min (SD 2.54) at 10 min to near zero at 120 and 240 min.Conclusion: HA with the HA380 cartridge can achieve an early 50% adsorption level for ticagrelor. If frequently changed, the HA380 cartridge may serve as a potential option for ticagrelor removal, when clinically indicated.","PeriodicalId":8953,"journal":{"name":"Blood Purification","volume":" ","pages":"226-230"},"PeriodicalIF":1.8000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Purification","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000544770","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/18 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Hemoadsorption has emerged as a potential intervention for the removal of ticagrelor. We aimed to evaluate the efficacy of the HA380 hemoadsorption cartridge for this purpose.

Methods: Six healthy adult sheep received 270 mg of ticagrelor via an orogastric tube, followed by hemoadsorption using a HA380 cartridge for a duration of 4 h. The sorbent-based removal ratio, clearance, and mass removal rate were assessed at multiple time points.

Results: The HA380 cartridge achieved an initial sorbent-based removal ratio of 48.9% (SD 11.8) at 10 min, which declined rapidly to 2.66% (SD 18.5) at 120 min and 0.48% (SD 17.0) at 240 min. Clearance followed a similar trend, starting at 46.1 mL/min (SD 11.4) and decreasing to 0.08 mL/min (SD 16.8) at 240 min. The mass removal rate also dropped significantly over time, from 3.74 ng/min (SD 2.54) at 10 min to near zero at 120 and 240 min.

Conclusion: HA with the HA380 cartridge can achieve an early 50% adsorption level for ticagrelor. If frequently changed, the HA380 cartridge may serve as a potential option for ticagrelor removal, when clinically indicated.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

HA380滤筒血液吸附去除替格瑞洛。

血液吸附已成为替格瑞洛去除的一种潜在干预手段。我们的目的是评估HA380血液吸附盒在这方面的疗效。方法：6只健康成年羊经胃管给予替格瑞洛270 mg， HA380吸附剂血液吸附4小时。在多个时间点评估基于吸附剂的去除率、清除率和质量去除率。结果：HA380滤芯在10分钟内的初始吸附剂去除率为48.9% (SD 11.8)，在120分钟和240分钟时迅速下降至2.66% （SD 18.5）和0.48% （SD 17.0）。清除率也有类似的趋势，从46.1 mL/min （SD 11.4）开始，在240分钟时降至0.08 mL/min （SD 16.8）。随着时间的推移，质量去除率也显著下降，从10分钟时的3.74 ng/min （SD 2.54）降至120和240分钟时的接近零。结论：HA380吸附剂对替格瑞洛的早期吸附水平可达50%。如果经常更换，HA380药筒可以作为替格瑞洛去除的潜在选择，当临床指证时。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Blood Purification 医学-泌尿学与肾脏学

CiteScore

5.80

自引率

3.30%

发文量

审稿时长

6-12 weeks

期刊介绍： Practical information on hemodialysis, hemofiltration, peritoneal dialysis and apheresis is featured in this journal. Recognizing the critical importance of equipment and procedures, particular emphasis has been placed on reports, drawn from a wide range of fields, describing technical advances and improvements in methodology. Papers reflect the search for cost-effective solutions which increase not only patient survival but also patient comfort and disease improvement through prevention or correction of undesirable effects. Advances in vascular access and blood anticoagulation, problems associated with exposure of blood to foreign surfaces and acute-care nephrology, including continuous therapies, also receive attention. Nephrologists, internists, intensivists and hospital staff involved in dialysis, apheresis and immunoadsorption for acute and chronic solid organ failure will find this journal useful and informative. ''Blood Purification'' also serves as a platform for multidisciplinary experiences involving nephrologists, cardiologists and critical care physicians in order to expand the level of interaction between different disciplines and specialities.